$4.06
3.31% yesterday
Nasdaq, Sep 26, 10:00 pm CET
ISIN
US46333X1081
Symbol
IRWD

Ironwood Pharmaceuticals Stock price

$4.06
-0.98 19.44% 1M
-4.26 51.20% 6M
-7.38 64.51% YTD
-5.34 56.81% 1Y
-9.43 69.90% 3Y
-4.58 53.01% 5Y
-6.81 62.66% 10Y
Nasdaq, Closing price Thu, Sep 26 2024
+0.13 3.31%
ISIN
US46333X1081
Symbol
IRWD
Sector
Industry

Key metrics

Market capitalization $648.54m
Enterprise Value $1.18b
P/E (TTM) P/E ratio 93.98
EV/FCF (TTM) EV/FCF 8.08
EV/Sales (TTM) EV/Sales 2.95
P/S ratio (TTM) P/S ratio 1.62
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth -6.25%
Revenue (TTM) Revenue $400.57m
EBIT (operating result TTM) EBIT $131.52m
Free Cash Flow (TTM) Free Cash Flow $146.36m
Cash position $105.52m
EPS (TTM) EPS $0.04
P/E forward 15.72
P/S forward 1.82
EV/Sales forward 3.32
Short interest 16.48%
Show more

Is Ironwood Pharmaceuticals a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,900 stocks worldwide.

Ironwood Pharmaceuticals Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Ironwood Pharmaceuticals forecast:

6x Buy
75%
2x Hold
25%

Analyst Opinions

8 Analysts have issued a Ironwood Pharmaceuticals forecast:

Buy
75%
Hold
25%

Financial data from Ironwood Pharmaceuticals

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
401 401
6% 6%
100%
- Direct Costs 2.04 2.04
62% 62%
1%
399 399
6% 6%
99%
- Selling and Administrative Expenses 142 142
2% 2%
36%
- Research and Development Expense 123 123
80% 80%
31%
134 134
39% 39%
33%
- Depreciation and Amortization 2.04 2.04
62% 62%
1%
EBIT (Operating Income) EBIT 132 132
39% 39%
33%
Net Profit 9.21 9.21
101% 101%
2%

In millions USD.

Don't miss a Thing! We will send you all news about Ironwood Pharmaceuticals directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Ironwood Pharmaceuticals Stock News

Neutral
Business Wire
28 days ago
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) will participate in a fireside chat at the 2024 Wells Fargo Healthcare Conference on Thursday, September 5, 2024 at 2:15 p.m. ET at the Encore Boston Harbor. A live webcast of Ironwood's fireside chat will be accessible through the Investors section of the company's website at www.ironwoodpharma.com. A replay of the webcast ...
Neutral
Seeking Alpha
about 2 months ago
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD ) Q2 2024 Earnings Conference Call August 8, 2024 8:30 AM ET Company Participants Matt Roache - Director of Investor Relations Tom McCourt - Chief Executive Officer Mike Shetzline - Chief Medical Officer Sravan Emany - Chief Operating Officer & Chief Financial Officer Andrew Davis - Chief Business Officer Conference Call Participants David Amsellem - ...
Neutral
Seeking Alpha
3 months ago
Ironwood Pharmaceuticals, Inc. data from the phase 2 proof-of-concept study, using CNP-104 for the treatment of patients with primary biliary cholangitis, expected in Q3 of 2024. The global primary biliary cholangitis therapeutics market size is projected to reach $1.4 billion by 2032. NDA filing and other regulatory filings across the globe of apraglutide for the treatment of patients with sho...
More Ironwood Pharmaceuticals News

Company Profile

Ironwood Pharmaceuticals, Inc. is a commercial biotechnology company, which engages in the discovery, commercialization, and development of medicines. Its products include linaclotide, a guanylate cyclase type-C agonists which treats patients irritable bowel syndrome with constipation and chronic constipation. The company was founded by Peter M. Hecht, Eric F. Summers, G. Todd Milne, Brian M. Cali, Joseph C. Cook Jr., and Gina Bornino Miller on January 5, 1998 and is headquartered in Boston, MA.

Head office United States
CEO Thomas McCourt
Employees 267
Founded 1998
Website www.ironwoodpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today